In-Hospital Mortality Up With Weekend Admission in NSTEMI

This article originally appeared here.
Share this content:
In-Hospital Mortality Up With Weekend Admission in NSTEMI
In-Hospital Mortality Up With Weekend Admission in NSTEMI

FRIDAY, Aug. 26, 2016 (HealthDay News) -- For patients with non-ST-segment elevation myocardial infarction (NSTEMI), weekend admission is associated with increased in-hospital mortality, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Sahil Agrawal, M.D., from St. Luke's University Health Network in Bethlehem, Penn., and colleagues used the Nationwide Inpatient Sample database to compare differences in all-cause in-hospital mortality for patients admitted on a weekend versus weekday for acute NSTEMI. A total of 3,625,271 NSTEMI admissions were identified: 25.1 and 74.9 percent were weekend and weekday admissions, respectively.

The researchers found that weekend versus weekday admission was independently associated with lower rates of coronary angiography (odds ratio [OR], 0.88; 95 percent confidence interval [CI], 0.89 to 0.90) or utilization of an early invasive strategy (EIS) (OR, 0.480; 95 percent CI, 0.47 to 0.48) (both P < 0.001). For the cohort of patients admitted on weekends, in-hospital mortality was significantly higher (adjusted OR, 1.02; 95 percent CI, 1.01 to 1.04). After adjustment for differences in rates of utilization of EIS, the disparity was no longer significant (OR, 1.01; 95 percent CI, 0.99 to 1.03).

"This study demonstrates that among patients admitted with a diagnosis of an acute NSTEMI, admission on a weekend was associated with higher in-hospital mortality compared with admission on a weekday, and that lower rates of utilization of EIS contributed significantly to this disparity," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »